29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
As Illinois set out to become the first state to legalize recreational cannabis through statutory au...
Read More >
Seyfarth Synopsis: The FCC has proposed new rules that would require employers to have compliant pho...
Read More >
The Delaware courts have not been shy about warning of the dangers that can arise when merger negoti...
Read More >
For decades, the problem of scheduling has plagued employers and employees alike. Employees prefer p...
Read More >
This webinar highlights risks and financial penalties associated with employee benefit programs. Emp...
Read More >
On December 16, 2019, the National Minimum Wage Commission (“CONASAMI” for its acronym in Spanish)...
Read More >